2017
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines
2016
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 214-221. PMID: 26895294, PMCID: PMC4866894, DOI: 10.1097/qai.0000000000000956.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsAntiretroviral therapyCell countAIDS-defining illnessAntiretroviral-naive individualsAIDS Research NetworkMortality hazard ratioHIV-positive personsIntegrated Clinical SystemsHIV-CAUSAL CollaborationVirologic outcomesHIV RNAVirologic failureHazard ratioClinical outcomesProspective studyRisk ratioHigh-income countriesEligible individualsMonths strategyMonthsIllnessDeathTherapy
2015
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, Collaboration H. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The Lancet HIV 2015, 2: e335-e343. PMID: 26423376, PMCID: PMC4643831, DOI: 10.1016/s2352-3018(15)00108-3.Peer-Reviewed Original ResearchConceptsNeed of ARTHIV RNA viral loadCD4 countAntiretroviral therapyHIV-positive individualsMean survival timeImmediate initiationHIV diagnosisCohort studyViral loadRelative riskHigh-income countriesProportion of individualsSurvival timeInitiation of ARTART initiation strategiesImmediate antiretroviral therapyLow CD4 countMedian CD4 countObservational cohort studyAIDS-free survivalHIV-1 infectionDiagnosis of HIVViral load measurementsHIV-CAUSAL CollaborationBoosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
Cain L, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins J, Sterne J, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán M. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 2015, 60: 1262-1268. PMID: 25567330, PMCID: PMC4447777, DOI: 10.1093/cid/ciu1167.Peer-Reviewed Original ResearchConceptsAtazanavir regimenVirologic failureProspective studyNucleoside reverse transcriptase inhibitor (NRTI) backboneFirst-line antiretroviral regimensReverse transcriptase inhibitor backboneAIDS-free individualsTreat hazard ratiosCD4 cell countCurrent clinical guidelinesHuman immunodeficiency virusRandomized clinical trialsAdjusted intentionAntiretroviral regimensAtazanavir groupBoosted atazanavirContaining RegimensVirologic outcomesCD4 countNRTI backboneHazard ratioClinical outcomesImmunodeficiency virusClinical guidelinesClinical trials
2012
Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases 2012, 54: 1364-1372. PMID: 22460971, PMCID: PMC3404691, DOI: 10.1093/cid/cis203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDeveloped CountriesDrug Therapy, CombinationEuropeFemaleHIV InfectionsHIV SeropositivityHumansImmune Reconstitution Inflammatory SyndromeIncidenceMaleMiddle AgedMycobacterium tuberculosisPneumocystis cariniiPneumonia, PneumocystisRNA, ViralTuberculosisUnited StatesViral LoadConceptsImmune reconstitution inflammatory syndromeCD4 cell countCells/μL.HIV RNA levelsHazard ratioTuberculosis incidenceCART initiationCell countAntiretroviral therapyTime-varying CD4 cell countBaseline CD4 cell countAIDS-free individualsEffects of CARTLow tuberculosis incidenceMonths of ARTReconstitution inflammatory syndromeHIV-positive patientsRNA levelsHIV-positive individualsHuman immunodeficiency virusHIV-CAUSAL CollaborationInflammatory syndromeImmunodeficiency virusInverse probability weightingPositive individuals
2011
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher H, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan M. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals Of Internal Medicine 2011, 154: 509-15. PMID: 21502648, PMCID: PMC3610527, DOI: 10.7326/0003-4819-154-8-201104190-00001.Peer-Reviewed Original ResearchConceptsCD4 cell countCombined end pointHazard ratioCell countCells/LAntiretroviral therapyCells/L.CD4 cell count thresholdBaseline CD4 cell countEnd pointVeterans Health Administration systemInitiation of cARTThreshold CD4 countCorresponding hazard ratiosMortality hazard ratioAIDS-free survivalProspective observational dataHIV-CAUSAL CollaborationMost clinical guidelinesHealth Administration systemUse of CD4Marginal structural modelsCell count thresholdCART initiationDynamic marginal structural models